{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:25:39Z","timestamp":1775478339299,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.critrevonc.2025.104741","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T16:02:17Z","timestamp":1745337737000},"page":"104741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials"],"prefix":"10.1016","volume":"211","author":[{"given":"Erman","family":"Akkus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nejat Emre","family":"\u00d6ks\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enes","family":"Erul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104741_bib1","unstructured":"NCCN, N.C.C.N., 2024. Colon Cancer, Verison 6.2024.."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104741_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7861\/fhj.10-3-s26","article-title":"Assessing the risk of bias in single-arm trials for systematic reviews: moving towards a more reliable evaluation of clinical evidence","volume":"10","author":"Alsinbili","year":"2023","journal-title":"Future Health J."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104741_bib3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104741_bib4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104741_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11523-024-01055-y","article-title":"Divarasib in the evolving landscape of KRAS G12C inhibitors for NSCLC","volume":"19","author":"Brazel","year":"2024","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104741_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104741_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.annonc.2023.10.129","article-title":"Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline","volume":"35","author":"Cervantes","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104741_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.annonc.2024.12.005","article-title":"ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann. Oncol."},{"issue":"10395","key":"10.1016\/j.critrevonc.2025.104741_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104741_bib10","article-title":"Development of KRAS inhibitors and their role for metastatic colorectal cancer","volume":"23","author":"Deming","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104741_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat. Med."},{"issue":"17_","key":"10.1016\/j.critrevonc.2025.104741_bib12","article-title":"Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator\u2019s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC)","volume":"42","author":"Fakih","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104741_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104741_bib14","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104741_bib15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann. Math. Stat."},{"issue":"9863","key":"10.1016\/j.critrevonc.2025.104741_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104741_bib17","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2024.42.16_suppl.3007","article-title":"Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors","volume":"42","author":"Heist","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104741_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"7414","key":"10.1016\/j.critrevonc.2025.104741_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"issue":"3_","key":"10.1016\/j.critrevonc.2025.104741_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1200\/JCO.2024.42.3_suppl.94","article-title":"Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study","volume":"42","author":"Hollebecque","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104741_bib21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104741_bib22","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2023.41.16_suppl.3513","article-title":"Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy","volume":"41","author":"Hong","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104741_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104741_bib24","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.21037\/apm-22-1390","article-title":"Palliative care in colorectal and anal malignancies from diagnosis to death","volume":"12","author":"Karlekar","year":"2023","journal-title":"Ann. Palliat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104741_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2025.104741_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104741_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104741_bib28","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104741_bib29","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"Bmj 372"},{"key":"10.1016\/j.critrevonc.2025.104741_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076754","article-title":"ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis","author":"Page","year":"2023","journal-title":"Bmj 383"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104741_bib31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/OP.24.00295","article-title":"Ready, set, go: setting off on the mission to target KRAS in colorectal cancer","volume":"20","author":"Pellatt","year":"2024","journal-title":"JCO Oncol. Pract."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104741_bib32","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104741_bib33","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104741_bib34","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/OP.23.00787","article-title":"Targeting KRAS oncogene for patients with colorectal cancer: a new step toward precision medicine","volume":"20","author":"Sahin","year":"2024","journal-title":"JCO Oncol. Pr."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104741_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"4_","key":"10.1016\/j.critrevonc.2025.104741_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.2025.43.4_suppl.131","article-title":"Adagrasib (Ada) +\u2009cetuximab (Cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1","volume":"43","author":"Yaeger","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104741_bib37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104741_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:29:10Z","timestamp":1749500950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":38,"alternative-id":["S1040842825001295"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104741","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104741"}}